MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to common...
-$6,078,593
(-69.51%↓ Y/Y)
Net loss
-$6,009,520
Series b convertible
preferred stock 8...
$69,073
Interest income
$7,388
(4.82%↑ Y/Y)
Other income
$3,740
Foreign currency gain
(loss)
$525
(115.43%↑ Y/Y)
Loss from operations
-$5,107,621
(-42.96%↓ Y/Y)
Realized loss on digital
assets
$904,394
Interest expense
$9,158
(-45.56%↓ Y/Y)
Total costs and
expenses
$5,107,621
(42.96%↑ Y/Y)
General and
administrative costs (includes...
$4,852,702
(70.48%↑ Y/Y)
Research and development
costs
$254,919
(-64.90%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)